Pixantrone: novel mode of action and clinical readouts

References

• Armitage JO, Gascoyne RD, Lunning MA, et al. Non-Hodgkin lymphoma. Lancet. 2017;390(10091):298–310.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Gascoyne RD. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood. 2015;125(1):22–32.
   PubMed Web of Science ®Google Scholar
• Tilly H, Gomes Da Silva M, Vitolo U, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v116–125.
   PubMed Web of Science ®Google Scholar
• Van Den Neste E, Pettengell R. Management of multiply relapsed aggressive non-Hodgkin lymphoma: new perspectives. EMJ. 2017;2(3):22–30.
   Google Scholar
• Pettengell R, Kaur J. Pixantrone dimaleate for treating non-Hodgkin’s lymphoma. Expert Opin Orphan Drugs. 2015;3(6):747–757.
   Web of Science ®Google Scholar
• D’amore F, Pettengell R. Optimising salvage therapy in aggressive B cell non-Hodgkin lymphoma. EMJ Oncol. 2016;4(1):47–55.
   Google Scholar
• European Medicines Agency. Pixuvri (pixantrone): summary of product characteristics. [Cited 2016]. Available from: http://www.ema.europa.eu/
   Google Scholar
• National Institute for Health and Care Excellence. Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin’s B-cell lymphoma. [Cited 2014]. Available from: http://www.nice.org.uk/guidance/ta306
   Google Scholar
• Menna P, Salvatorelli E, Minotti G. Rethinking drugs from chemistry to therapeutic opportunities: pixantrone beyond anthracyclines. Chem Res Toxicol. 2016;29(8):1270–1278.
   PubMed Web of Science ®Google Scholar
• Patel AG, Kaufmann SH. How does doxorubicin work? eLIFE. 2012;1(e00387).
   PubMedGoogle Scholar
• Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol. 1999;57(7):727–741.
   PubMed Web of Science ®Google Scholar
• Sawyer DB. Anthracyclines and heart failure. N Engl J Med. 2013;368(12):1154–1156.
   PubMed Web of Science ®Google Scholar
• Pogorelcnik B, Perdih A, Solmajer T. Recent developments of DNA poisons–human DNA topoisomerase IIalpha inhibitors–as anticancer agents. Curr Pharm Des. 2013;19(13):2474–2488.
   PubMed Web of Science ®Google Scholar
• Minotti G, Menna P, Salvatorelli E, et al. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004;56(2):185–229.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Novantrone (mitoxantrone): summary of product characteristics. [Cited 2016]. Available from: http://www.ema.europa.eu/
   Google Scholar
• Faulds D, Balfour JA, Chrisp P, et al. Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs. 1991;41(3):400–449.
   PubMed Web of Science ®Google Scholar
• De Isabella P, Palumbo M, Sissi C, et al. Topoisomerase II DNA cleavage stimulation, DNA binding activity, cytotoxicity, and physico-chemical properties of 2-aza- and 2-aza-oxide-anthracenedione derivatives. Mol Pharmacol. 1995;48(1):30–38.
   PubMed Web of Science ®Google Scholar
• Hazlehurst LA, Krapcho AP, Hacker MP. Comparison of aza-anthracenedione-induced DNA damage and cytotoxicity in experimental tumor cells. Biochem Pharmacol. 1995;50(7):1087–1094.
   PubMed Web of Science ®Google Scholar
• Beeharry N, Zhu X, Murali V, et al. Pixantrone induces cell death through mitotic perturbations and subsequent aberrant cell divisions in solid tumor cell lines. Mol Cancer Ther. 2013;12(11 Supplement):A147.
   Web of Science ®Google Scholar
• Ng S, Munoz R, Von Hoff D, et al. Mechanism of action of pixantrone in non-Hodgkin’s lymphoma cells. Presented at: American Association for Cancer Research (AACR) Annual Meeting; Apr 1–5; Washington, DC, USA; 2017.
   Google Scholar
• Evison BJ, Bilardi RA, Chiu FC, et al. CpG methylation potentiates pixantrone and doxorubicin-induced DNA damage and is a marker of drug sensitivity. Nucleic Acids Res. 2009;37(19):6355–6370.
   PubMed Web of Science ®Google Scholar
• Evison BJ, Chiu F, Pezzoni G, et al. Formaldehyde-activated Pixantrone is a monofunctional DNA alkylator that binds selectively to CpG and CpA doublets. Mol Pharmacol. 2008;74(1):184–194.
   PubMed Web of Science ®Google Scholar
• Evison BJ, Mansour OC, Menta E, et al. Pixantrone can be activated by formaldehyde to generate a potent DNA adduct forming agent. Nucleic Acids Res. 2007;35(11):3581–3589.
   PubMed Web of Science ®Google Scholar
• Adnan N, Buck DP, Evison BJ, et al. DNA binding by pixantrone. Org Biomol Chem. 2010;8(23):5359–5366.
   PubMed Web of Science ®Google Scholar
• Beeharry N, Di Rora AG, Smith MR, et al. Pixantrone induces cell death through mitotic perturbations and subsequent aberrant cell divisions. Cancer Biol Ther. 2015;16(9):1397–1406.
   PubMed Web of Science ®Google Scholar
• Volpetti S, Zaja F, Fanin R. Pixantrone for the treatment of adult patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphomas. Onco Targets Ther. 2014;7:865–872.
   PubMed Web of Science ®Google Scholar
• Beggiolin G, Crippa L, Menta E, et al. Bbr 2778, an aza-anthracenedione endowed with preclinical anticancer activity and lack of delayed cardiotoxicity. Tumori. 2001;87(6):407–416.
   PubMed Web of Science ®Google Scholar
• Hacker M, Mckennon M, Singer JW. Lack of iron binding by pixantrone is associated with reduced production of reactive oxygen species and myocyte cytotoxicity in vitro. Blood. 2009;114:4806.
   Google Scholar
• Hasinoff BB, Wu X, Patel D, et al. Mechanisms of action and reduced cardiotoxicity of pixantrone; a topoisomerase II targeting agent with cellular selectivity for the topoisomerase IIα isoform. J Pharmacol Exp Ther. 2016;356(2):397–409.
   PubMed Web of Science ®Google Scholar
• Longo M, Della Torre P, Allievi C, et al. Tolerability and toxicological profile of pixantrone (Pixuvri®) in juvenile mice. Comparative study with doxorubicin. Reprod Toxicol. 2014;46:20–30.
   PubMed Web of Science ®Google Scholar
• Cavalletti E, Crippa L, Mainardi P, et al. Pixantrone (BBR 2778) has reduced cardiotoxic potential in mice pretreated with doxorubicin: comparative studies against doxorubicin and mitoxantrone. Invest New Drugs. 2007;25(3):187–195.
   PubMed Web of Science ®Google Scholar
• Borchmann P, Morschhauser F, Parry A, et al. Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin’s lymphomas. Haematologica. 2003;88(8):888–894.
   PubMed Web of Science ®Google Scholar
• Pettengell R, Coiffier B, Narayanan G, et al. Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial. Lancet Oncol. 2012;13(7):696–706.
   PubMed Web of Science ®Google Scholar
• Keating GM. Pixantrone: a review in relapsed or refractory aggressive non-Hodgkin’s lymphoma. Drugs. 2016;76(16):1579–1586.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Corradini P, Martelli M, et al. Critical concepts, practice recommendations, and research perspectives of pixantrone therapy in non-Hodgkin lymphoma: a SIE, SIES, and GITMO consensus paper. Eur J Haematol. 2016;97(6):554–561.
   PubMed Web of Science ®Google Scholar
• Eyre TA, Linton KM, Rohman P, et al. Results of a multicentre UK-wide retrospective study evaluating the efficacy of pixantrone in relapsed, refractory diffuse large B cell lymphoma. Br J Haematol. 2016;173(6):896–904.
   PubMed Web of Science ®Google Scholar
• Pettengell R, Sebban C, Zinzani PL, et al. Monotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: post-hoc analyses from a phase III trial. Br J Haematol. 2016;174(5):692–699.
   PubMed Web of Science ®Google Scholar
• Pettengell R, Narayanan G, Mendoza FH, et al. Randomized phase III trial of pixantrone compared with other chemotherapeutic agents for third-line single-agent treatment of relapsed aggressive non-Hodgkin’s lymphoma. J Clin Oncol. 2009;27(15 suppl):8523–8523.
   PubMed Web of Science ®Google Scholar
• Belada D, Georgiev P, Dakhil S, et al. Pixantrone-rituximab versus gemcitabine-rituximab in relapsed/refractory aggressive non-Hodgkin lymphoma. Future Oncol. 2016;12(15):1759–1768.
   PubMed Web of Science ®Google Scholar
• Reagan PM, Friedberg JW. Reassessment of anti-CD20 therapy in lymphoid malignancies: impact, limitations, and new directions. Oncology. 2017;31(5):402–411.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Venturini F, Stefoni V, et al. Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. Ann Oncol. 2010;21(4):860–863.
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.Gov. GOAL: GA101 plus pixantrone for relapsed aggressive lymphoma [NCT02499003]. [Cited 2017]. Available from: https://clinicaltrials.gov/ct2/show/NCT02499003
   Google Scholar
• Clinicaltrials.Gov. IIT CTI bendamustine, rituximab, pixantrone in relapsed/refractory B cell non-Hodgkin’s lymphoma (BRP) [NCT01491841]. [Cited 2017]. Available from: https://clinicaltrials.gov/ct2/show/NCT01491841
   Google Scholar
• Malisza KL, Hasinoff BB. Production of hydroxyl radical by iron(III)-anthraquinone complexes through self-reduction and through reductive activation by the xanthine oxidase/hypoxanthine system. Arch Biochem Biophys. 1995;321(1):51–60.
   PubMed Web of Science ®Google Scholar
• Salvatorelli E, Menna P, Paz OG, et al. The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: insight to explain the cardiac safety of pixantrone in doxorubicin-treated patients. J Pharmacol Exp Ther. 2013;344(2):467–478.
   PubMed Web of Science ®Google Scholar
• Zhang S, Liu X, Bawa-Khalfe T, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012;18(11):1639–1642.
   PubMed Web of Science ®Google Scholar
• Atwal M, Lishman EL, Austin CA, et al. Myeloperoxidase enhances etoposide and mitoxantrone-mediated DNA damage: a target for myeloprotection in cancer chemotherapy. Mol Pharmacol. 2017;91(1):49–57.
   PubMedGoogle Scholar
• Damiani RM, Moura DJ, Viau CM, et al. Pathways of cardiac toxicity: comparison between chemotherapeutic drugs doxorubicin and mitoxantrone. Arch Toxicol. 2016;90(9):2063–2076.
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Cernohous P, Engert A, et al. Comparison of pixantrone-based regimen (CPOP-R) with doxorubicin-based therapy (CHOP-R) for treatment of diffuse large B-cell lymphoma. Ann Oncol. 2013;24(10):2618–2623.
   PubMed Web of Science ®Google Scholar
• Borchmann P, Herbrecht R, Wilhelm M, et al. Phase I/II study of pixantrone in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin lymphoma. Leuk Lymphoma. 2011;52(4):620–628.
   PubMed Web of Science ®Google Scholar
• Lim ST, Fayad L, Tulpule A, et al. A phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin’s lymphoma. Leuk Lymphoma. 2007;48(2):374–380.
   PubMed Web of Science ®Google Scholar
• Srokowski TP, Liebmann JE, Modiano MR, et al. Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: phase 1 study with a dose-expansion cohort. Cancer. 2011;117(22):5067–5073.
   PubMed Web of Science ®Google Scholar
• Boyle EM, Morschhauser F. Pixantrone: a novel anthracycline-like drug for the treatment of non-Hodgkin lymphoma. Expert Opin Drug Saf. 2015;14(4):601–607.
   PubMed Web of Science ®Google Scholar
• Clinical Trials.Gov. Phase 1/2 study of the combination of pixantrone, etoposide, bendamustine, and in CD20 positive tumors, rituximab in patients with relapsed aggressive non-Hodgkin lymphomas of B- or T-cell phenotype - the P[R]EBEN study [NCT02678299]. [Cited 2017]. Available from: https://clinicaltrials.gov/ct2/show/NCT02678299
   Google Scholar
• Clausen M, Leppa S, Brown P, et al. The combination of pixantrone, etoposide, bendamustine and, in CD20+ tumors, rituximab (PREBEN) shows promising feasibility/efficacy in heavily pre-treated aggressive lymphomas of B- and T-cell phenotype - results of the pre-trial experience leading to a Nordic Phase 1/2 study (the PREBEN trial). Blood. 2016;128(22):1782.
   PubMed Web of Science ®Google Scholar
• Tarantelli C, Gaudio E, Kwee I, et al. Combinations containing the aza-anthracenedione pixantrone show preclinical activity in diffuse large B-cell lymphoma. Cancer Res. 2016;76(14 Supplement):4793.
   Google Scholar
• Minotti G, Menna P, Salvatorelli E. Do you know pixantrone? Chemotherapy. 2017;62:192–193.
   PubMed Web of Science ®Google Scholar